Amenorrhea Medications Market Size, Share, and Industry Analysis, By Drug Class (Progestins, Dopamine Receptor Agonist, and Others), By Indication (Primary Amenorrhea and Secondary Amenorrhea), By Route of Administration (Oral, Vaginal, and Parenteral), By Distribution Channel (Hospital Pharmacy, Drug Stores & Retail Pharmacies, and Online Pharmacy), and Regional Forecast, 2026-2034

The global amenorrhea medications market growth is driven by advancements in hormonal therapy. Amenorrhea refers to the lack of a menstrual period. It is not a disease but rather a symptom of another underlying condition, such as polycystic ovary syndrome (PCOS) or Fragile X-associated primary ovarian insufficiency (FXPOI). Primary amenorrhea refers to failure to start menstruation by the age of 16, whereas secondary amenorrhea describes women experiencing an absence of more than three menstrual cycles after having regular periods.

The amenorrhea medications are drugs prescribed to treat the absence of menstrual periods (amenorrhea). These drugs work by correcting underlying hormonal imbalances, stimulating ovulation, or addressing conditions associated with Amenorrhea. Additionally, increasing awareness of female reproductive health and menstruation, along with increasing diagnoses, are expected to propel market growth.

Amenorrhea Medications Driver

Rising Prevalence of Amenorrhea Due to PCOS and Hormonal Imbalance to Heighten the Demand for Medications and Drive Market Growth

The rising prevalence of PCOS and hormonal imbalances has led to an increasing diagnosis of amenorrhea. A considerable (13%) share of women of productive age suffer from PCOS. It disrupts ovulation through insulin resistance and excess androgen production, leading directly to irregular or absent menstrual cycles. Furthermore, hormonal disturbances involving estrogen, progesterone, thyroid, or prolactin disrupt the menstrual cycle, which can manifest as amenorrhea. As more women face infertility risks, endometrial complications, and bone health issues linked to untreated amenorrhea, the demand for effective medications continues to rise. This increasing disease burden, coupled with heightened awareness and early diagnosis, is fueling growth in the global amenorrhea medications market. 

The Burden of Comorbidities Associated with PCOS (%)

In October 2024, Jama Network Open published an article that reported that in a cross-sectional study of 9,824 women aged 18 to 40 years, the weighted national prevalence of PCOS by the National Institutes of Health 1990 and Rotterdam 2003 criteria was 7.2% and 19.6%, respectively. Among women with PCOS, 43.2% had obesity, 91.9% had dyslipidemia, 32.9% had nonalcoholic fatty liver disease, 24.9% had metabolic syndrome, 3.4% had diabetes, and 8.3% had hypertension, and PCOS with phenotype C was most prevalent.

Amenorrhea Medications Restraint

Adverse Effects Associated with Administration of Medications to Restrict Growth Potential

One of the prominent factors restraining the growth of the market is the adverse effects associated with the administration of amenorrhea medications. These medications can cause Thrombophlebitis, Insomnia, sleepiness, fatigue, Nervousness, Vaginal secretions, Breast tenderness, and secretion. Recent studies have reported additional side effects such as brain tumors. Such a factor restrains the market growth.

• For example, in August 2025, a lawsuit was filed against Pfizer Inc. after a study reported that Depo-Provera, an amenorrhea medication, can cause brain tumors.

Amenorrhea Medications Opportunity

Research and Development for the Development of Novel Treatment Alternatives to Offer Lucrative Growth Opportunities in Market

The current therapies offered for the treatment of amenorrhea are largely restricted to hormonal contraceptives, Progestins, ovulation-inducing agents, and insulin sensitizers. These alternatives assisted in the cycle. As awareness of women’s reproductive health grows, patients and clinicians are seeking safer, more targeted, and long-term treatment alternatives. This unmet clinical need is driving pharmaceutical and biotech companies to invest in research and development (R&D) for novel drug classes, non-hormonal therapies, and personalized medicine approaches. Many key companies are pooling their resources toward research initiatives to offer an effective alternative.

• For instance, in March 2023, Ferring Pharmaceutical conducted clinical trials to compare the ovulation rate in women with primary amenorrhea with hypogonadotropic hypogonadism following pulsatile gonadotropin-releasing hormone (GnRH) treatment using the Omni Pod pump versus placebo.

Key Insights

The report covers the following key insights:

• Epidemiology of Amenorrhea
• Overview: Current Treatment Therapies
• Pipeline Analysis, By Key Players
• Women's Health Guidelines, Associated with PCOS
• Key Industry Development (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

Analysis by Drug Class

By drug class, the market is divided into progestins, dopamine receptor agonists, and others.

Progestins are expected to grow significantly over the forecast period of the global amenorrhea medications market. The drug class is the first line of the recommended treatment regimen. The progestins restore hormonal balance and induce withdrawal bleeding.

• For instance, in 2019, American Family Physician published an article titled ‘Amenorrhea: A Systematic Approach to Diagnosis and Management’, which recommended the use of cyclic oral progestin to improve bone density in amenorrhea patients. 

Analysis by Indication

The global amenorrhea medications market is classified into primary amenorrhea and secondary amenorrhea on the basis of indication. The secondary amenorrhea is expected to account for a significant share of the market due to a higher prevalence than other causes. Also, the diagnosis rate is higher for secondary amenorrhea. Such factors contributed to the segment's growth in the market.

On the other hand, girls with primary amenorrhea typically do not have symptoms of estrogen deficiency. However, with inadequate estrogen exposure over time, these patients are at increased risk for developing osteoporosis and possibly other health issues.

Analysis by Route of Administration

Based on route of administration, the amenorrhea medications market is further divided into oral, vaginal, and parenteral. The oral segment is expected to grow substantially over the forecast period. The high growth of the segment is predominantly due to numerous offerings for amenorrhea medications that are administered orally.

• For example, PROVERA tablets containing medroxyprogesterone acetate, a derivative of progesterone, are indicated for the treatment of secondary amenorrhea. This drug is administered in oral route of administration.

Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacy, drug stores & retail pharmacies, and online pharmacy.

Hospital pharmacy is expected to hold a significant market share. Hospital pharmacy provides a stop experience for all the hormonal replacement therapies, oral medications, and other treatment regimes. Additionally, advancements to enhance operational efficiency are undertaken, highlighting the importance of hospital pharmacies. Such factors drive the growth of the segment. 

• For instance, in December 2024, Cencora launched Accelerate Pharmacy Solutions, a unified portfolio of solutions designed to help hospital and health systems customers optimize operations. Such developments, facilitating hospital pharmacy operations, propel the growth of the segment.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest global amenorrhea medication share in 2024. The growth of the market in the region is due to the increasing prevalence of amenorrhea and increasing cases of hormonal imbalance. Also, the robust infrastructure and high healthcare spending support the regional dominance in the market. To cater to this high demand, generics for the treatment of amenorrhea were launched in the region.

• For instance, in October 2018, Mylan N.V. launched Medroxyprogesterone Acetate Injectable Suspension USP, a generic version of Pfizer's Depo-Provera. Indicated in the prevention of pregnancy in the U.S.

Europe is expected to grow with a considerable CAGR during the forecast period. The region's high market share is increasing prevalence of PCOS in the region. Hormonal imbalance, stress, and other factors influence the growth of the market. Also, the government plans to facilitate growth.

• For instance, in June 2023, the list of medicines covered by the HRT prepayment certificate was updated, and Gepretix, an estrogen plus progestin therapy, was added to the list—such developments support the growth of the market in the region.

Asia Pacific is expected to grow with a substantial CAGR during the forecast period. The regional growth is attributed to rising awareness of menstrual health and increased healthcare spending, such factors to improve the diagnosis and support the growth of the amenorrhea medication market. 

Key Players Covered

The global amenorrhea medications market is consolidated with the presence of a few established companies. The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)
• Abbvie Inc. (U.S.)
• Hikma Pharmaceuticals PLC (U.K.) 
• Teva Pharmaceutical Industries Ltd (Israel)
• Aurobindo Pharma Limited. (India)
• Sanofi (France)

Key Industry Developments

• In October 2024, Renata PLC launched a generic version of Cabergoline 0.5 mg, a medicine used for the treatment of hyperprolactinemia, amenorrhea in Australia.
• In January 2019, Cipla Limited received approval for its Abbreviated New Drug Application (ANDA) for Medroxyprogesterone Injectable, 150mg/mL from the U.S. FDA. The drug is a generic therapeutic equivalent version of Pfizer’s Depo-Provera.